Premas Biotech
Business Services · Connecticut, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
13 High Field Ln, Madison, Connecticut, ...Phone Number
+91 1244546600Website
www.premasbiotech.comRevenue
$31.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Premas Biotech
Premas Biotech develops novel technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic & vaccine candidates. Premas' key focus areas are infectious diseases, cancer, metabolic disorders and inflammation. Besides D-Crypt the difficult to express proteins expression platform, Premas' leading technologies include Axtex-4D: an ex-vivo tissueoid generation platform and C-Qwence: a fully human naive India based scFv antibody library.Explore more
Premas Biotech Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Premas Biotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Premas Biotech has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Premas Biotech launches new products
Funding: Get notified immidiatlly once Premas Biotech has new funding data
Earning: See what the market has to say on Premas Biotech recently announced quarterly report
Click to see if Premas Biotech had a recent Job posting/layoffs
Check out if Premas Biotech is spiking on competitors!
Premas Biotech, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Premas Biotech
Recommended Actions
Find VP level buyers at Premas Biotech
Find 2 more new buyers
Compare Similar Companies to Premas Biotech
Compare insights from companies similar to Premas Biotech, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$10.8M
51-200
Private
-
1997
AY
Amy YokoyamaAssistant Director, UC Davis Mouse Biology Program Repository & Project Management
Company Profile Activity
Activity Insights
Premas Biotech is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Premas Biotech is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Premas Biotech.
Premas Biotech Tech Stack
A closer look at the technologies used by Premas Biotech
Most Recent Scoops
Event
Events
Event
will be attending the 15th Annual PEGS Europe 2023 conference as an exhibitor. The event will occur from November 14 to November 16, 2023.
Events
Event
will be attending the 22nd Annual PepTalk 2023 conference as an exhibitor. The event will occur from January 16 to January 20, 2023.
Events
Project
A mid-level source has indicated that the organization is planning to automate the existing request for proposal (RFP) processes.
Automation
Project
Sales
Premas Biotech News & Media
Oramed Will Soon Start Clinical Trials For Oral COVID-19 Vaccine In Israel, Out licensed Injectable Version To Premas Biotech In India
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) announced several updates for its majority-owned company Oravax Medical Inc. read morePremas Biotech and Oramed Announce Oral COVID-19 Vaccine Candidate That Produces Antibodies After a Single Dose
GURUGRAM, India--(BUSINESS WIRE)-- #Antibodies--Premas Biotech and Oramed announce Oral COVID-19 vaccine candidate that produces Antibodies after a single dose.Akers Biosciences and Premas Biotech Announce SARS CoV-2 Positive Proof of Concept Results
Thorofare, New Jersey, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced with its partner, Premas Biotech, positive proof of concept results from Animal Studies conducted during a 4 week test of its SARS-CoV-2 vaccine candidate in mice. The test had two primary endpoints, safety and immune response, both of which were met. The candidate was well tolerated and safe in mice
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Premas Biotech
Sign Up For FreeTo access detailed company insights
Premas Biotech develops novel technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic & vaccine candidates. Premas' key focus areas are infectious diseases, cancer, metabolic disorders and inflammation. Besides D-Crypt the difficult to express proteins expression platform, Premas' leading technolo... Read More
